Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...

Top-line findings from the ICESECRET clinical trial (NCT02399124) featuring the ProSense Cryoablation System for the ...

FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...

Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy ...

Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...

In patients with marginal zone lymphoma (MZL), venetoclax (Venclexta) plus ibrutinib (Imbruvica) demonstrated safety and ...

Week-18 ORR equivalence was achieved for HD204 vs reference bevacizumab (48.7% vs 46.5%), with both risk ratio and risk ...

With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...

Theriva Biologics has received FDA agreement on the core design elements of a pivotal Phase 3 trial evaluating zabilugene ...

Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into ...

Relacorilant plus nab-paclitaxel achieved a 35% reduction in mortality risk with a 4.1-month median overall survival ...